Beam Therapeutics Inc. (BEAM) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $30.84: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 34%; Below-average business quality.
Beam Therapeutics is a pre-commercial biotech developing base-editing genetic medicines. Lead programs are risto-cel (autologous HSC for sickle cell disease, BLA targeted year-end 2026) and BEAM-302 (in vivo LNP for alpha-1 antitrypsin deficiency in Phase 1/2). No products are... Read more
Sell if holding. Engine safety override at $30.84: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 34%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Score 4.6/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineristo-cel sickle cell BLA10-K Item 1: 'We expect to submit a BLA for risto-cel as early as year-end 2026'
Material Events(8-K, last 90d)
- 2026-03-05Item 1.02MEDIUMOn March 2, 2026, Beam and Bio Palette Co. mutually terminated their base editing License Agreement due to Bio Palette's planned dissolution. A standby license from Kobe University simultaneously activated, preserving Beam's rights under the same scope.SEC filing →
- 2026-02-05Item 5.02LOWCarole Ho resigned from Beam Board effective February 27, 2026. No disagreement with Company on any matter relating to operations, policies or practices. No successor named for board seat.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $30.84: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 34%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Prior stop was $28.66. Score 4.6/10, moderate confidence.
Take-profit target: $46.08 (+49.5% upside). Prior stop was $28.66. Stop-loss: $28.66.
Concentration risk — Pipeline: risto-cel sickle cell BLA; Quality below floor (1.8 < 4.0).
Beam Therapeutics Inc. trades at a P/E of N/A (forward -6.7). TrendMatrix value score: 5.4/10. Verdict: Sell.
25 analysts cover BEAM with a consensus score of 4.3/5. Average price target: $51.
What does Beam Therapeutics Inc. do?Beam Therapeutics is a pre-commercial biotech developing base-editing genetic medicines. Lead programs are risto-cel...
Beam Therapeutics is a pre-commercial biotech developing base-editing genetic medicines. Lead programs are risto-cel (autologous HSC for sickle cell disease, BLA targeted year-end 2026) and BEAM-302 (in vivo LNP for alpha-1 antitrypsin deficiency in Phase 1/2). No products are approved and no certified product sales revenue has been recognized.